Cirrhosis News and Research

Latest Cirrhosis News and Research

Magnetic resonance: A good method for detecting and quantifying fats in the liver

Obesity and overweight affect more than half of the population in our Community. Excess weight causes important alterations in the organism, one of which affects liver function. Fat accumulates in the liver producing hepatic steatosis which, in certain circumstances, causes inflammation, fibrosis and finally, cirrhosis.

18 Sep 2014

T-bet protein fights off hepatitis infections

A single protein may tip the balance between ridding the body of a dangerous virus and enduring life-long chronic infection, according to a report appearing in The Journal of Experimental Medicine.

16 Sep 2014

Ramucirumab Phase III study meets primary endpoint in patients with metastatic colorectal cancer

Eli Lilly and Company today announced that the RAISE trial, a Phase III study of ramucirumab (CYRAMZA) in combination with chemotherapy in patients with metastatic colorectal cancer (mCRC), met its primary endpoint of overall survival.

15 Sep 2014

Researchers examine whether new drug offers added benefit for patients with chronic HCV

The drug simeprevir has been available since May 2014 for the treatment of adult patients with chronic hepatitis C infection.

9 Sep 2014

Novira completes Phase 1a clinical study of NVR-1221 for treatment of HBV infection

Novira Therapeutics, Inc., a privately held biopharmaceutical company developing novel therapies for curative treatment of chronic hepatitis B virus (HBV) infection, today announced successful completion of a Phase 1a clinical study of NVR-1221.

4 Sep 2014

Bristol-Myers Squibb launches Daklinza in the UK for treatment of chronic hepatitis C

Bristol-Myers Squibb today announced the launch of Daklinza▼ (daclatasvir) in the UK, a new medicine for the treatment of adult patients with chronic hepatitis C. Daclatasvir, a treatment that works across multiple hepatitis C genotypes, will allow up to 90% of UK patients the option of a potentially curative oral treatment regimen that does not include interferon, a standard of care commonly associated with sustained flu-like side effects.

4 Sep 2014

Research findings call for clinical testing of relevant drugs to prevent NASH

Non-alcoholic fatty liver disease (NAFLD) is a common affliction, affecting almost 30 percent of Americans, with a significant number suffering from its most severe form, called non-alcoholic steatohepatitis or NASH, which can lead to cirrhosis and liver cancer. In recent years, NASH has become the leading cause of liver transplantation.

19 Aug 2014

First Edition: August 14, 2014

Today's headlines include a report about an uptick in VA referrals to private physicians. Kaiser Health News staff writer Julie Appleby reports: "Some hospitals in New York, Florida and Wisconsin are exploring ways to help individuals and families pay their share of the costs of government-subsidized policies purchased though the health law's marketplaces – at least partly to guarantee the hospitals get paid when the consumers seek care.

14 Aug 2014

New technique for studying lifecycle of hepatitis B virus can help develop cure for disease

A new technique for studying the lifecycle of the hepatitis B virus could help researchers develop a cure for the disease.

5 Aug 2014

MUP policy for alcohol is targeted towards heaviest drinkers with cirrhosis

A new study of liver patients by the University of Southampton shows that a Minimum Unit Price (MUP) policy for alcohol is exquisitely targeted towards the heaviest drinkers with cirrhosis.

1 Aug 2014

New pill-only antiviral drug regimens could cure hardest-to-treat hepatitis C

Two new pill-only antiviral drug regimens could provide shorter, more effective treatment options with fewer side effects for the majority of patients infected with hepatitis C, even those most difficult to treat, according to the results of two studies published in The Lancet.

29 Jul 2014

New study in recognition of World Hepatitis Day released on Life Sciences Connect

The Intellectual Property and Science business of Thomson Reuters, the world's leading source of intelligent information for businesses and professionals, today released a new study in recognition of World Hepatitis Day on Life Sciences Connect, a blog exploring the latest news and trends in Life Sciences and updates on the drug pipeline identifying multiple treatments in development that may serve as potential alternatives to Gilead's Sovaldi, currently priced in the United States at $84,000 for 12 weeks of treatment - $1000 per pill.

28 Jul 2014

Researchers provide global genotype prevalence estimates for HCV

In one of the largest prevalence studies to date, researchers from the U.K. provide national, regional, and global genotype prevalence estimates for the hepatitis C virus (HCV). Findings published in Hepatology, a journal of the American Association for the Study of Liver Diseases, indicate that genotype 1 is the most prevalent worldwide, with over 83 million patients infected of which one-third reside in East Asia.

28 Jul 2014

Scientists find high proportion of oral bacteria in gut microbiota of liver cirrhosis patients

Scientists from INRA in collaboration with a Chinese team found that the gut microbiota[1] of individuals with liver cirrhosis differ notably from healthy individuals', showing a high proportion of oral bacteria.

26 Jul 2014

Trinidad & Tobago Ministry of Health approves hepatitis C drug telaprevir

The Chemistry, Food & Drugs Division of the Trinidad & Tobago Ministry of Health approved the introduction of Telaprevir to the market, an innovative therapy that significantly increases the cure rate from Hepatitis C, and it is indicated for patients infected with the genotype 1 virus. Telaprevir is available in Trinidad under the trade brand INCIVO®.

26 Jul 2014

RI Defeats Hepatitis C project aims to eliminate HCV in Rhode Island

Lynn E. Taylor, M.D., director of The Miriam Hospital's HIV/Viral Hepatitis Coinfection program, states in the July, 2014 Rhode Island Medical Journal special edition, "RI Defeats Hep C" that eliminating hepatitis c virus infection (hep c or HCV) is feasible, can provide economic benefits, enhance capacity to address other health challenges, and improve health care disparities.

26 Jul 2014

Unique bacterial biomarkers may help develop diagnostics, treatments for liver cirrhosis

ENTEROME Bioscience SA, a pioneer in the development of innovative disease management solutions based on a deep understanding of the gut microbiome, and with a strong focus on liver diseases, highlights the advanced online publication in Nature of a research paper describing the identification of a unique series of bacterial biomarkers that could provide new opportunities for the development of diagnostics and treatments for liver cirrhosis.

26 Jul 2014

New momentum: WHO welcomes progress in tackling viral hepatitis

On World Hepatitis Day, 28 July, WHO welcomes new progress in tackling one of the world's most serious diseases. Viral hepatitis - a group of infectious diseases known as hepatitis A, B, C, D, and E - affects millions of people worldwide, causing acute and chronic liver disease and killing close to 1.4 million people every year.

23 Jul 2014

Tackling hepatitis C: an interview with Gaston Picchio, Global Hepatitis Disease Area Leader at Janssen

Gaston Picchio outlines the major findings of the recent report published by The Economist Intelligence Unit (EIU): ‘Tackling hepatitis C: Moving towards an integrated policy approach’

23 Jul 2014

Drug for reduction of abdominal fat in HIV patients may also reduce fatty liver disease

The only drug to receive FDA approval for reduction of the abdominal fat deposits that develop in some patients receiving antiviral therapy for HIV infection may also reduce the incidence of fatty liver disease in such patients.

21 Jul 2014

Cirrhosis News and Research

Latest Cirrhosis News and Research

Magnetic resonance: A good method for detecting and quantifying fats in the liver

T-bet protein fights off hepatitis infections

Ramucirumab Phase III study meets primary endpoint in patients with metastatic colorectal cancer

Researchers examine whether new drug offers added benefit for patients with chronic HCV

Novira completes Phase 1a clinical study of NVR-1221 for treatment of HBV infection

Bristol-Myers Squibb launches Daklinza in the UK for treatment of chronic hepatitis C

Research findings call for clinical testing of relevant drugs to prevent NASH

First Edition: August 14, 2014

New technique for studying lifecycle of hepatitis B virus can help develop cure for disease

MUP policy for alcohol is targeted towards heaviest drinkers with cirrhosis

New pill-only antiviral drug regimens could cure hardest-to-treat hepatitis C

New study in recognition of World Hepatitis Day released on Life Sciences Connect

Researchers provide global genotype prevalence estimates for HCV

Scientists find high proportion of oral bacteria in gut microbiota of liver cirrhosis patients

Trinidad & Tobago Ministry of Health approves hepatitis C drug telaprevir

RI Defeats Hepatitis C project aims to eliminate HCV in Rhode Island

Unique bacterial biomarkers may help develop diagnostics, treatments for liver cirrhosis

New momentum: WHO welcomes progress in tackling viral hepatitis

Tackling hepatitis C: an interview with Gaston Picchio, Global Hepatitis Disease Area Leader at Janssen

Drug for reduction of abdominal fat in HIV patients may also reduce fatty liver disease

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Cirrhosis News and Research

Latest Cirrhosis News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in